Neuroendocrine Carcinomas: Patient Journey And Treatment Outcomes In Latin America
NECTARINE
1 other identifier
observational
200
4 countries
19
Brief Summary
This observational, retrospective study aims to understand the treatment patterns and outcomes of patients with pulmonary and extra-pulmonary neuroendocrine carcinomas (NEC) in Latin America (Brazil, Mexico, Argentina, and Peru). The research will collect data from medical records to analyze factors like patient demographics, diagnosis methods, tumor characteristics, treatment approaches, and disease progression. The study is non-interventional, meaning patient care will follow standard clinical practice, with data gathered via an electronic system.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P75+ for all trials
Started Dec 2025
Shorter than P25 for all trials
19 active sites
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
February 17, 2025
CompletedFirst Posted
Study publicly available on registry
September 25, 2025
CompletedStudy Start
First participant enrolled
December 16, 2025
CompletedPrimary Completion
Last participant's last visit for primary outcome
September 1, 2026
CompletedStudy Completion
Last participant's last visit for all outcomes
September 1, 2026
CompletedSeptember 8, 2026
August 1, 2026
9 months
February 17, 2025
September 2, 2026
Conditions
Outcome Measures
Primary Outcomes (6)
Patterns of Initial Cancer Treatment: number of participants treated within vs. outside high-volume sites and associated treatment characteristics
Treatment patterns will be analyzed descriptively using tables and graphs to illustrate the distribution of patients receiving initial cancer treatment within versus outside high-volume treatment centers. Key characteristics of the initial treatment will be assessed.
Throughout the study period, an average of 24 months
Event-free survival (EFS)
defined as time from diagnosis until relapse, death, or definitive failure of treatment strategy that implicates failure of curative-intent treatment \[for patients treated with curative intent\]. Participants who are lost to follow up or reach the study end will be censored at their last date of contact.
Throughout the study period, an average of 24 months
Time to treatment failure (TTF)
in first and second-line: defined as time from first dose of treatments until date of discontinuation of treatment for any reason, including progression of disease, treatment toxicity, and death. Participants who are lost to follow up or reach the study end will be censored at their last date of contact
Throughout the study period, an average of 24 months
Progression-free survival (PFS)
defined as time from treatment initiation until progression or death \[for patients treated with palliative intent\]. Participants who are lost to follow up or reach the study end will be censored at their last date of contact.
Throughout the study period, an average of 24 months
Overall survival
\[according to disease stage/setting\], defined as time from initial diagnosis until date of death from any cause. Participants who are lost to follow up or reach the study end will be censored at their last date of contact.
Throughout the study period, an average of 24 months
Frequency of DLL-3 immunohistochemistry expression
Rate of patients with DLL3 expression in extra-pulmonary and pulmonary NEC by IHC \[stratified by tumor primary site\]
After the end of recruitment, an average of 1 year
Study Arms (2)
Patients with extra-pulmonary neuroendocrine carcinoma
Patients with Extrapulmonary Neuroendocrine Carcinoma (EP-NEC), diagnosed between August 2014 and August 2024.
Patients with pulmonary neuroendocrine carcinoma
Patients with Large-cell neuroendocrine carcinoma (LCNEC) or mixed and patients with Small Cell Lung Cancer (SCLC) or mixed, diagnosed between August 2014 and August 2024.
Interventions
This is an observational study; patients will not be exposed to clinical interventions different from those belonging to the standard of care.
Eligibility Criteria
Patients with extra-pulmonary neuroendocrine carcinoma (EP-NEC) and patients with pulmonary neuroendocrine carcinoma (SCLC or LCNEC) from Brazil, Mexico, Argentina and Peru.
You may qualify if:
- ≥18 years old
- Diagnosed between August 2014 and August 2024 with one of the following:
- Extrapulmonary Neuroendocrine Carcinoma (EP-NEC)
- Large-cell neuroendocrine carcinoma (LCNEC) or mixed
- Small Cell Lung Cancer (SCLC) or mixed
- Adequate and accessible medical records for data collection
- Tumor block collected from 2014 onwards
You may not qualify if:
- Patients with active, concurrent malignancies at the time of NEC diagnosis, except for non-invasive cancers like basal cell carcinoma or squamous cell carcinoma of the skin, or in situ cervical cancer.
- Patients or their legal representatives unwilling or unable to provide informed consent (if needed per ethics committee).
Contact the study team to confirm eligibility.
Sponsors & Collaborators
- Latin American Cooperative Oncology Grouplead
- Boehringer Ingelheimcollaborator
- Grupo Argentino de Investigación Clínica en Oncologíacollaborator
- Grupo de Estudios Clínicos Oncológicos Peruanocollaborator
Study Sites (19)
Hospital Británico de Buenos Aires
Buenos Aires, Buenos Aires, Argentina
Hospital de Gastroenterología Carlos Bonorino Udaondo
Buenos Aires, Buenos Aires, Argentina
Instituto Alexander Fleming
Buenos Aires, Buenos Aires, Argentina
Hospital Evangélico de Cachoeiro de Itapemirim - Centro de Pesquisas Clínicas em Oncologia (CPCO)
Cachoeiro de Itapemirim, Espírito Santo, 29308-065, Brazil
Clínica Prognóstica - Centro de Pesquisa Clínica Onconeo
Campo Grande, Mato Grosso do Sul, 79002-061, Brazil
Oncocentro de Minas Gerais (Oncoclínicas)
Belo Horizonte, Minas Gerais, 30360-680, Brazil
IOP Pesquisa - Instituto de Oncologia do Paraná
Curitiba, Paraná, 80040-170, Brazil
HCL - Hospital do Câncer de Londrina
Londrina, Paraná, 86015-520, Brazil
INCA - Instituto Nacional de Câncer
Rio de Janeiro, Rio de Janeiro, 20230-130, Brazil
HUOL - Hospital Universitário Onofre Lopes da UFRN
Natal, Rio Grande do Norte, 59012-300, Brazil
Liga Norte Riograndense Contra o Câncer
Natal, Rio Grande do Norte, 59062-000, Brazil
HMV - Hospital Moinhos de Vento
Porto Alegre, Rio Grande do Sul, 90035-001, Brazil
Futtura Oncologia - Hub de Pesquisa Clínica
Porto Alegre, Rio Grande do Sul, 90470-340, Brazil
ANIMI - Unidade de Tratamento Oncológico
Lages, Santa Catarina, 88501-001, Brazil
A.C. Camargo Cancer Center
São Paulo, São Paulo, 01509-001, Brazil
HIAE - Hospital Israelita Albert Einstein
São Paulo, São Paulo, Brazil
Centro Oncológico Internacional (COI)
Mexico City, Mexico City, Mexico
INCan - Instituto Nacional de Cancerología
Mexico City, Mexico City, Mexico
Oncosalud AUNA
Lima, Lima Province, Peru
Biospecimen
Tumor block: Formalin-Fixed Paraffin-Embedded collected from 2014 onwards.
MeSH Terms
Conditions
Interventions
Condition Hierarchy (Ancestors)
Intervention Hierarchy (Ancestors)
Study Officials
- PRINCIPAL INVESTIGATOR
Rachel Simões Pimenta Riechelmann
Latin American Cooperative Oncology Group
- PRINCIPAL INVESTIGATOR
Vladmir Cláudio Cordeiro de Lima
Latin American Cooperative Oncology Group
Central Study Contacts
Study Design
- Study Type
- observational
- Observational Model
- CASE ONLY
- Time Perspective
- RETROSPECTIVE
- Sponsor Type
- OTHER
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
February 17, 2025
First Posted
September 25, 2025
Study Start
December 16, 2025
Primary Completion
September 1, 2026
Study Completion
September 1, 2026
Last Updated
September 8, 2026
Record last verified: 2026-08